Advances in CAR-T Cell Therapy for Solid Tumors
Immune Discovery · 2025
DOI: 10.70322/immune.2025.10006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immune Discovery, 2025. Verfasst von Yitong Li und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 158 Literaturangaben.
Abstract (Originalsprache)
Chimeric Antigen Receptor T (CAR-T) cell therapy represents a groundbreaking advancement in cancer treatment, demonstrating remarkable antitumor efficacy in hematological malignancies. However, despite the substantial clinical progress achieved with CAR-T cell therapy, its application in the treatment of solid tumors remains limited by various factors, including the intricate tumor microenvironment (TME), CAR-T cell exhaustion, CAR-T cell infiltration into tumor tissue, and antigen heterogeneity. Scientists are relentlessly pursuing research in this domain, driven by the aim of offering newfound hope to cancer patients. In this comprehensive review, we delineate the fundamental principles underlying CAR-T cell therapy, delve into the challenges it encounters, and provide an insightful exploration of the advancements and progress made in the application of CAR-T cell therapy for solid tumors.
Zitieren
APA
Li, Y., Zuo, B., Xing, Y., Zhang, R., Jia, L., Yan, B., Yang, A., & Yin, H. (2025). Advances in CAR-T Cell Therapy for Solid Tumors. Immune Discovery. https://doi.org/10.70322/immune.2025.10006
Vancouver
Li Y, Zuo B, Xing Y, Zhang R, Jia L, Yan B, et al. Advances in CAR-T Cell Therapy for Solid Tumors. Immune Discovery. 2025. doi:10.70322/immune.2025.10006
BibTeX
@article{Li2025,
author = {Li, Yitong and Zuo, Baile and Xing, Yating and Zhang, Rui and Jia, Lintao and Yan, Bo and Yang, Angang and Yin, Huilong},
title = {Advances in CAR-T Cell Therapy for Solid Tumors},
journal = {Immune Discovery},
year = {2025},
doi = {10.70322/immune.2025.10006}
}
EUVIMED